# Bortezomib Followed by High-Dose Melphalan and Bortezomib as Conditioning Regimen for Tandem Stem Cell Transplants

> **NCT00307086** · PHASE2 · COMPLETED · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 30 (actual)

## Conditions studied

- Multiple Myeloma
- Plasma Cell Leukemia

## Interventions

- **DRUG:** Bortezomib
- **DRUG:** Melphalan
- **PROCEDURE:** PBSCT

## Key facts

- **NCT ID:** NCT00307086
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-06
- **Primary completion:** 2012-03
- **Final completion:** 2012-03
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2017-03-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00307086

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00307086, "Bortezomib Followed by High-Dose Melphalan and Bortezomib as Conditioning Regimen for Tandem Stem Cell Transplants". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT00307086. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*